This week in therapeutics

Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Multiple myeloma (MM)

Proteasome

In vitro and mouse studies identified a homopiperazine proteasome inhibitor that could help treat drug-resistant MM. In cultured, bortezomib-resistant MM cell lines and in mouse xenograft models of MM, the proteasome inhibitor blocked proliferation and decreased tumor volume compared with vehicle. Next steps include testing the molecule in additional mouse models of cancer.
Takeda Pharmaceutical Co. Ltd. and Johnson & Johnson market the proteasome inhibitor Velcade bortezomib to treat MM and mantle cell lymphoma (MCL).
Onyx Pharmaceuticals Inc. and Ono Pharmaceutical Co. Ltd. market the proteasome inhibitor Kyprolis carfilzomib to treat MM.

SciBX 6(33); doi:10.1038/scibx.2013.889
Published online Aug. 29, 2013

Patent and licensing status unavailable

Kikuchi, J. et al. J. Biol. Chem.; published online July 22, 2013;
doi:10.1074/jbc.M113.480574
Contact: Yusuke Furukawa, Jichi Medical University, Tochigi, Japan
e-mail:

furuyu@jichi.ac.jp